Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).

Current oncology reports - 11 Apr 2026

Vyas Abhinav, Jeon Won Jin, Alhushki Sanad, Singhi Eric, Rous Fawzi Abu, Thawani Rajat, Desai Aakash

Abstract excerpt

PURPOSE OF REVIEW: With the approvals of various targeted therapies including tyrosine kinase inhibitors to antibody–drug conjugates, the treatment landscape of patients with EGFR-mutant non-small cell lung cancer has drastically improved. The use of EGFR-targeted therapies has shifted to include not only advanced/ metastatic disease but also to early-stage non-small cell lung cancer. RECENT FINDINGS: Novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41964727
DOI: 10.1007/s11912-026-01751-0
PMCID: PMC13070087

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).PMID 41964727Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Emerging targeted therapies in non-small cell lung cancer.Semantic proximity Read ↗

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewSemantic proximity Read ↗

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.Semantic proximity Read ↗

Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.Semantic proximity Read ↗

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Semantic proximity Read ↗

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.